Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders... Show more
Bristol Myers Squibb's third-quarter results offer a critical read on how well the company is navigating the transition from its Legacy Portfolio toward a newer, faster-growing set of medicines. The quarter tested whether double-digit momentum in the Growth Portfolio could offset generic pressure on older blockbusters such as Revlimid and the conversion of Opdivo sales to the newer Opdivo Qvantig formulation. With Eliquis facing a loss of exclusivity in Europe later this year, investors are also watching closely to understand how the company plans to sustain revenue and profitability as patent protection erodes on some of its largest products.
Bristol Myers Squibb reported third-quarter 2026 revenue of $13.07 billion, up 7% from $12.22 billion in the prior-year period and ahead of the $12.72 billion consensus estimate. Adjusted earnings per share (EPS) reached $1.35, beating the $1.09 analysts had projected, while GAAP (Generally Accepted Accounting Principles) diluted EPS came in at $1.05.
Growth Portfolio revenue increased 12% to $7.7 billion, supported by strong performances from Breyanzi (up 48% to $526 million), Reblozyl (up 22% to $750 million), and Camzyos (up 42% to $420 million). The Legacy Portfolio grew 1% to $5.4 billion, with Eliquis rising 25% to $4.69 billion. Adjusted gross margin declined to 68.4% from 72.9%, reflecting a change in product mix and a one-time charge tied to a contract termination.
Management raised its full-year 2026 revenue outlook to a range of $49.75 billion to $50.25 billion, up from the prior $49.0 billion to $50.0 billion. The company also updated its adjusted EPS guidance to $6.35–$6.55, which incorporates a negative $0.60 per-share impact from acquired in-process research and development (IPR&D) charges and licensing income.
Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. If you are looking to streamline your research and uncover potential setups across the healthcare sector and beyond, the AI Screener can be a practical starting point.
The market responded positively to the report, with Bristol Myers Squibb shares rising more than 2% following the announcement. Investors appeared encouraged by the top- and bottom-line beats, the 12% growth in the Growth Portfolio, and the upward revision to full-year revenue guidance. At the same time, the decline in adjusted gross margin and the updated EPS guidance midpoint of $6.45—slightly below the $6.49 analyst consensus—tempered some of the enthusiasm, reflecting ongoing pressure from product mix shifts and the near-term Eliquis exclusivity headwind in Europe.
Looking ahead, investors will be watching several catalysts that could shape Bristol Myers Squibb's trajectory over the coming quarters. First is the Eliquis loss of exclusivity in Europe during the fourth quarter, which management has flagged as a potential $1.5 billion to $2 billion step-down in revenue. How quickly the broader portfolio offsets that decline will be a central theme.
Second, the company's late-stage pipeline continues to advance. Recent positive readouts for Zenbexus (iberdomide) in relapsed/refractory multiple myeloma, admilparant in idiopathic pulmonary fibrosis, and arlo-cel in relapsed and refractory multiple myeloma add potential growth drivers, while the company expects additional Phase 3 data for milvexian in secondary stroke prevention and Sotyktu in lupus before year-end.
Finally, margin trends and cost discipline remain important. Management continues to execute a $2 billion productivity initiative, and the quarter's strong operating cash flow of roughly $4.2 billion—alongside a cash position of about $13 billion—provides strategic flexibility. Investors will likely monitor whether Growth Portfolio momentum, pipeline execution, and expense management can together sustain profitability as legacy products face increasing generic competition.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a manufacturer of pharmaceuticals products
Industry PharmaceuticalsMajor